10.05.2022 - -Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022- -FDA Permits Treatment with LUM-201 Beyond 12 Months and Lifts Partial Clinical Hold- -Clinical .
Theravive - Therapy News And Blogging - New research presented at the 59th Annual European Society for Paediatric Endocrinology Meeting looked at the link between an increased risk of heart disease and stress hormone sensitivity. The study has been published in the Journal of Hormone Research in Paediatrics. “In clinical practice, healthy subjects are characterized by differences in glucocorticoid sensitivity that may influence the therapeutic outcome and any adverse effects of synthetic glucocorticoids,” study author Nicolas C. Nicolaides told us. “Thus, it would be very helpful for clinicians to have a fast and accurate methodology that would enable the classification of individuals based on their tissue sensitivity to glucocorticoids."
How to Improve the Fertility of Obese Boys in the Future? medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.